WO2000027819A2 - Anthranilsäureamide und deren verwendung als arzneimittel - Google Patents
Anthranilsäureamide und deren verwendung als arzneimittel Download PDFInfo
- Publication number
- WO2000027819A2 WO2000027819A2 PCT/EP1999/008478 EP9908478W WO0027819A2 WO 2000027819 A2 WO2000027819 A2 WO 2000027819A2 EP 9908478 W EP9908478 W EP 9908478W WO 0027819 A2 WO0027819 A2 WO 0027819A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- stands
- hydrogen
- halogen
- methyl
- Prior art date
Links
- 0 *N(c1ccccc1C(O1)=O)C1=O Chemical compound *N(c1ccccc1C(O1)=O)C1=O 0.000 description 2
- VHVCBKQJCOKLTD-UHFFFAOYSA-N CN(c1nc(Br)c(cccc2)c2c1)c1c(cccc2)c2cc(N)n1 Chemical compound CN(c1nc(Br)c(cccc2)c2c1)c1c(cccc2)c2cc(N)n1 VHVCBKQJCOKLTD-UHFFFAOYSA-N 0.000 description 1
- UAUJZFNYIBXEDG-UHFFFAOYSA-N C[n](cc1)c(cc2)c1cc2Cl Chemical compound C[n](cc1)c(cc2)c1cc2Cl UAUJZFNYIBXEDG-UHFFFAOYSA-N 0.000 description 1
- CSUGQXMRKOKBFI-UHFFFAOYSA-N C[n]1ncc2c1cccc2 Chemical compound C[n]1ncc2c1cccc2 CSUGQXMRKOKBFI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2001063917A UA71587C2 (uk) | 1998-11-10 | 1999-09-11 | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
PL99348349A PL348349A1 (en) | 1998-11-10 | 1999-11-09 | Antrhranilic acid amides and the use thereof as medicaments |
BR9915553-2A BR9915553A (pt) | 1998-11-10 | 1999-11-09 | Amidas de ácido antranìlico e seu emprego como medicamento |
JP2000580999A JP2002529452A (ja) | 1998-11-10 | 1999-11-09 | アントラニル酸アミド及び医薬剤としてのその使用 |
NZ511413A NZ511413A (en) | 1998-11-10 | 1999-11-09 | Antrhranilic acid amides and the use thereof as medicaments |
HU0104425A HUP0104425A3 (en) | 1998-11-10 | 1999-11-09 | Anthranilic acid amides and the use thereof for the treatment of angiogenesis |
EA200100524A EA004701B1 (ru) | 1998-11-10 | 1999-11-09 | Амиды антраниловой кислоты и их применение в качестве лекарственных средств |
AU10454/00A AU771180B2 (en) | 1998-11-10 | 1999-11-09 | Antrhranilic acid amides and the use thereof as medicaments |
EP99953967A EP1129074A2 (de) | 1998-11-10 | 1999-11-09 | Anthranilsäureamide und deren verwendung als arzneimittel |
CA002350208A CA2350208A1 (en) | 1998-11-10 | 1999-11-09 | Antrhranilic acid amides and the use thereof as medicaments |
EEP200100258A EE200100258A (et) | 1998-11-10 | 1999-11-09 | Antraniilhappe amiidid ja nende kasutamine ravimitena |
SK607-2001A SK6072001A3 (en) | 1998-11-10 | 1999-11-09 | Anthranilic acid amides and the use thereof as medicaments |
US09/831,506 US7122547B1 (en) | 1998-11-10 | 1999-11-09 | Anthranilic acid amides and the use thereof as medicaments |
NO20012245A NO320647B1 (no) | 1998-11-10 | 2001-05-07 | Anthranilsyreamider og anvendelse derav for fremstilling av medikamenter |
HK02103628A HK1041882A1 (en) | 1998-11-10 | 2002-05-14 | Anthranilic acid amides and their use in manufacturing pharmaceutical agents. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9824579.8A GB9824579D0 (en) | 1998-11-10 | 1998-11-10 | Organic compounds |
GB9824579.8 | 1998-11-10 | ||
DE19910396.8 | 1999-03-03 | ||
DE1999110396 DE19910396C2 (de) | 1999-03-03 | 1999-03-03 | Anthranilsäureamide und deren Verwendung als Arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000027819A2 true WO2000027819A2 (de) | 2000-05-18 |
WO2000027819A3 WO2000027819A3 (de) | 2000-08-17 |
Family
ID=26052266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/008478 WO2000027819A2 (de) | 1998-11-10 | 1999-11-09 | Anthranilsäureamide und deren verwendung als arzneimittel |
Country Status (23)
Cited By (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085719A1 (de) * | 2000-05-09 | 2001-11-15 | Schering Aktiengesellschaft | Ortho substituierte anthranilsäureamide und deren verwendung als arzneimittel |
WO2001085671A2 (de) * | 2000-05-09 | 2001-11-15 | Schering Aktiengesellschaft | Anthranylamide und deren verwendung als arzneimittel |
WO2001097786A2 (en) * | 2000-06-21 | 2001-12-27 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
WO2002046181A2 (en) * | 2000-12-07 | 2002-06-13 | Cv Therapeutics, Inc. | Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
WO2002066470A1 (en) * | 2001-01-12 | 2002-08-29 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002090352A2 (de) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
WO2002090349A1 (de) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel |
DE10123587A1 (de) * | 2001-05-08 | 2002-11-21 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel |
DE10123573A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel |
WO2002100833A1 (fr) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
WO2002055501A3 (en) * | 2001-01-12 | 2002-12-19 | Amgen Inc. | N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
WO2003000678A1 (de) * | 2001-05-08 | 2003-01-03 | Schering Aktiengesellschaft | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
WO2002068406A3 (en) * | 2001-01-12 | 2003-04-24 | Amgen Inc | Substituted amine derivatives and their use for the treatment of angiogenesis |
WO2004005279A2 (en) * | 2002-07-09 | 2004-01-15 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
WO2004007481A2 (en) * | 2002-07-17 | 2004-01-22 | Amgen Inc. | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
WO2004007458A1 (en) | 2002-07-17 | 2004-01-22 | Amgen Inc. | Substituted 2-alkylamine nicotinic amide derivatives and use there of |
EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
DE10235690A1 (de) * | 2002-07-31 | 2004-02-19 | Schering Ag | VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide |
WO2004050610A2 (en) * | 2002-12-04 | 2004-06-17 | Gene Logic Inc. | Modulators of melanocortin receptor |
WO2004063330A2 (en) | 2003-01-06 | 2004-07-29 | Osi Pharmaceuticals, Inc. | (2-carboxamido) (3-amino) thiophene compounds |
WO2004072069A1 (en) * | 2003-02-14 | 2004-08-26 | Glaxo Group Limited | Carboxamide derivatives |
WO2004078723A1 (ja) | 2003-03-07 | 2004-09-16 | Santen Pharmaceutical Co. Ltd. | 4-ピリジルアルキルチオ基を置換基として有する新規化合物 |
US6818661B2 (en) * | 2000-05-09 | 2004-11-16 | Novartis Ag | Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors |
WO2004103306A2 (en) | 2003-05-19 | 2004-12-02 | Irm Llc | Immunosuppressant compounds and compositions |
WO2004108133A2 (en) * | 2003-06-05 | 2004-12-16 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
WO2004111005A1 (de) * | 2003-06-13 | 2004-12-23 | Schering Aktiengesellschaft | Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyridone |
WO2005000833A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
WO2005004864A1 (en) * | 2003-07-11 | 2005-01-20 | Merck Patent Gmbh | Benzimidazole derivatives as raf kinase inhibitors |
WO2004069792A3 (en) * | 2003-02-03 | 2005-01-20 | Janssen Pharmaceutica Nv | Quinoline-derived amide modulators of vanilloid vr1 receptor |
US6864255B2 (en) | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
WO2005047273A1 (en) * | 2003-11-14 | 2005-05-26 | Novartis Ag | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors |
WO2005054179A2 (en) | 2003-12-03 | 2005-06-16 | Leo Pharma A/S | Hydroxamic acid esters and pharmaceutical use thereof |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
WO2005085202A1 (de) * | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Pyridinamid-derivate als kinase-inhibitoren |
WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
WO2006047574A1 (en) | 2004-10-26 | 2006-05-04 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-amino) thiophene compounds |
US7087761B2 (en) | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
US7094789B2 (en) | 2002-07-22 | 2006-08-22 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivatives |
US7101868B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US7129245B2 (en) * | 1998-12-23 | 2006-10-31 | Eli Lilly And Company | Aromatic amides |
US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
CN1300113C (zh) * | 2001-11-08 | 2007-02-14 | 诺瓦提斯公司 | 邻氨基苯甲酰胺和其作为vegf受体酪氨酸激酶抑制剂的用途 |
WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
US7238808B2 (en) | 2005-03-23 | 2007-07-03 | Hoffmann-La Roche Inc. | Acetylenyl-pyrazolo-pyrimidine derivatives |
WO2007107543A1 (en) | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
US7368446B2 (en) | 2004-05-24 | 2008-05-06 | Hoffmann-La Roche Inc. | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
JP2008518894A (ja) * | 2004-11-03 | 2008-06-05 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Vegf受容体キナーゼインヒビターとしてのアントラニルアミドピリジンウレア |
JP2008518893A (ja) * | 2004-11-03 | 2008-06-05 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 血管内皮成長因子(vegf)受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア |
EP1944026A2 (en) | 2002-05-16 | 2008-07-16 | Novartis AG | Use of EDG receptor binding agents in cancer |
WO2008093677A1 (ja) | 2007-01-29 | 2008-08-07 | Santen Pharmaceutical Co., Ltd. | 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体 |
EP1975166A1 (en) * | 2007-03-30 | 2008-10-01 | Bayer Schering Pharma AG | Synthesis of anthranilamides |
US7459563B2 (en) | 2004-11-05 | 2008-12-02 | Hoffmann-La Roche Inc. | Process for the preparation of isonicotinic acid derivatives |
EP2022498A2 (en) | 2005-11-21 | 2009-02-11 | Novartis AG | Neuroendocrine tumour treatment |
US7504404B2 (en) | 2005-09-27 | 2009-03-17 | Hoffmann-La Roche Inc. | Compounds as metabotropic glutamate receptor antagonists |
US7544703B2 (en) | 2004-02-17 | 2009-06-09 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein |
US7572794B2 (en) | 2004-11-03 | 2009-08-11 | Bayer Schering Pharma Ag | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
WO2010022725A1 (en) | 2008-08-27 | 2010-03-04 | Leo Pharma A/S | Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
WO2010043050A1 (en) | 2008-10-16 | 2010-04-22 | Celator Pharmaceuticals Corporation | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
WO2010071794A1 (en) | 2008-12-18 | 2010-06-24 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
WO2010080455A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | New salts |
WO2010080409A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid |
EP2210643A2 (en) | 2001-07-19 | 2010-07-28 | Novartis AG | Combinations comprising epothilones and pharmaceutical uses thereof |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
EP2253319A1 (en) | 2001-05-16 | 2010-11-24 | Novartis AG | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. |
WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
EP2269603A1 (en) | 2001-02-19 | 2011-01-05 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
EP2270008A1 (en) | 2005-05-20 | 2011-01-05 | Novartis AG | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors |
EP2272511A1 (en) | 2006-05-09 | 2011-01-12 | Novartis AG | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
WO2011015652A1 (en) | 2009-08-07 | 2011-02-10 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators |
WO2011018454A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
WO2011022439A1 (en) | 2009-08-17 | 2011-02-24 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
US7897774B2 (en) | 2005-03-03 | 2011-03-01 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having quinolylalkylthio group |
WO2011023677A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
US7906511B2 (en) | 2005-03-31 | 2011-03-15 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having pyrimidinylalkylthio group |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
WO2011029915A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
EP2308855A1 (en) | 2002-03-15 | 2011-04-13 | Novartis AG | 2,4-Diaminopyrimidine derivatives |
WO2011054828A1 (en) | 2009-11-04 | 2011-05-12 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
WO2011064211A1 (en) | 2009-11-25 | 2011-06-03 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
WO2011070030A1 (en) | 2009-12-08 | 2011-06-16 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2011076786A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
US7989462B2 (en) | 2003-07-03 | 2011-08-02 | Myrexis, Inc. | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP2359818A1 (en) | 2007-02-15 | 2011-08-24 | Novartis AG | Combination of LBH589 with HSP 90 inhibitors for treating cancer |
WO2011157793A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2011157787A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
EP2409969A1 (en) | 2004-06-24 | 2012-01-25 | Novartis AG | Pyrimidine urea derivatives as kinase inhibitors |
US8106190B2 (en) * | 2005-11-30 | 2012-01-31 | Astellas Pharma Inc. | 2-aminobenzamide derivatives |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012066095A1 (en) | 2010-11-19 | 2012-05-24 | Novartis Ag | Crystalline form of an inhibitor of mdm2/4 and p53 interaction |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
WO2012120469A1 (en) | 2011-03-08 | 2012-09-13 | Novartis Ag | Fluorophenyl bicyclic heteroaryl compounds |
WO2012149413A1 (en) | 2011-04-28 | 2012-11-01 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
WO2012168884A1 (en) | 2011-06-09 | 2012-12-13 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
WO2013096049A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096059A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096055A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096051A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096060A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EP2628726A1 (en) | 2008-03-26 | 2013-08-21 | Novartis AG | Hydroxamate-based inhibitors of deacetylases b |
US8541442B2 (en) | 2009-02-04 | 2013-09-24 | Janssen Pharmaceutica N.V. | Indole derivatives as anticancer agents |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
US8853406B2 (en) | 2007-08-06 | 2014-10-07 | Janssen Pharmaceutica Nv | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53 |
WO2015022662A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2016016822A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
EP3064502A1 (en) | 2012-01-26 | 2016-09-07 | Novartis AG | Imidazopyrrolidinone compounds |
US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
WO2019077037A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY |
WO2019119486A1 (zh) | 2017-12-21 | 2019-06-27 | 中国科学院合肥物质科学研究院 | 一类嘧啶类衍生物激酶抑制剂 |
EP3797765A1 (en) | 2006-06-27 | 2021-03-31 | Novartis AG | S1p receptor modulators for treating multiple sclerosis |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7427390B2 (en) * | 2004-03-10 | 2008-09-23 | Schering Ag | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy |
DE102004011720B4 (de) * | 2004-03-10 | 2008-04-03 | Bayer Schering Pharma Aktiengesellschaft | Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie |
DE102004039876A1 (de) * | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
JP5156378B2 (ja) | 2004-09-22 | 2013-03-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | MDM2とp53の間の相互作用の阻害剤 |
US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
JP5162574B2 (ja) * | 2006-03-22 | 2013-03-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Mdm2及びp53間の相互作用のインヒビターとしての環式アルキルアミン誘導体 |
WO2008077809A1 (en) * | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Process for the manufacture of 7-oxa-bicyclo derivatives |
CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
KR102061353B1 (ko) | 2010-09-10 | 2020-01-02 | 에피자임, 인코포레이티드 | 인간 ezh2의 억제제 및 이의 사용 방법 |
EP2681216B1 (en) | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
CN102603729A (zh) * | 2012-01-12 | 2012-07-25 | 贵州大学 | N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物 |
LT3184523T (lt) | 2012-04-13 | 2020-02-10 | Epizyme Inc | N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui |
TWI588131B (zh) | 2012-10-15 | 2017-06-21 | 雅酶股份有限公司 | 經取代苯化合物 |
CN103130696B (zh) * | 2013-03-21 | 2014-06-11 | 山东大学 | 邻氨基苯甲酰胺类化合物及其制备方法与应用 |
CN103405434A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | Vegfr-2抑制剂及其用途 |
PL3057962T3 (pl) | 2013-10-16 | 2024-01-29 | Epizyme, Inc. | Postać soli chlorowodorku do inhibicji ezh2 |
CN104163794A (zh) * | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
CA3166630A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
WO2022222890A1 (en) * | 2021-04-19 | 2022-10-27 | Shanghai Yao Yuan Biotechnology Co., Ltd. | Benzothiazole and quinoline derivatives for use in treating kawasaki disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3409668A (en) * | 1964-11-07 | 1968-11-05 | Palazzo Giuseppe | Substituted anthranilamides and process for the preparation thereof |
DE2652144A1 (de) * | 1976-11-16 | 1978-05-18 | Merck Patent Gmbh | Neue chinazolindione |
DE3406416A1 (de) * | 1983-02-28 | 1984-08-30 | American Cyanamid Co., Wayne, N.J. | N-((omega)-(1h-imidazol-l-yl)-alkyl)-arylamide |
EP0564356A1 (fr) * | 1992-04-01 | 1993-10-06 | Fournier Industrie Et Sante | Dérivés de 4-phénylaminométhylimidazole, procédé de préparation, antagonistes des récepteurs angiotensin II et leur application en thérapeutique |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3226394A (en) * | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
JPS5744672B2 (US07122547-20061017-C00064.png) | 1974-05-24 | 1982-09-22 | ||
US4568687A (en) * | 1983-02-28 | 1986-02-04 | American Cyanamid Company | N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions |
CA2155662A1 (en) * | 1993-12-27 | 1995-07-06 | Fumihiro Ozaki | Anthranilic acid derivative |
WO1997034895A1 (de) * | 1996-03-15 | 1997-09-25 | Novartis Ag | NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
-
1999
- 1999-09-11 UA UA2001063917A patent/UA71587C2/uk unknown
- 1999-11-09 KR KR1020017005800A patent/KR100777476B1/ko not_active IP Right Cessation
- 1999-11-09 BR BR9915553-2A patent/BR9915553A/pt not_active Application Discontinuation
- 1999-11-09 EE EEP200100258A patent/EE200100258A/xx unknown
- 1999-11-09 PL PL99348349A patent/PL348349A1/xx not_active Application Discontinuation
- 1999-11-09 KR KR1020077015852A patent/KR100855396B1/ko not_active IP Right Cessation
- 1999-11-09 EA EA200100524A patent/EA004701B1/ru not_active IP Right Cessation
- 1999-11-09 EP EP99953967A patent/EP1129074A2/de not_active Withdrawn
- 1999-11-09 CA CA002350208A patent/CA2350208A1/en not_active Abandoned
- 1999-11-09 TR TR2001/01307T patent/TR200101307T2/xx unknown
- 1999-11-09 SK SK607-2001A patent/SK6072001A3/sk unknown
- 1999-11-09 YU YU31801A patent/YU31801A/sh unknown
- 1999-11-09 HU HU0104425A patent/HUP0104425A3/hu unknown
- 1999-11-09 NZ NZ511413A patent/NZ511413A/en unknown
- 1999-11-09 AU AU10454/00A patent/AU771180B2/en not_active Ceased
- 1999-11-09 US US09/831,506 patent/US7122547B1/en not_active Expired - Fee Related
- 1999-11-09 CN CNB998130788A patent/CN1151133C/zh not_active Expired - Fee Related
- 1999-11-09 JP JP2000580999A patent/JP2002529452A/ja not_active Withdrawn
- 1999-11-09 WO PCT/EP1999/008478 patent/WO2000027819A2/de not_active Application Discontinuation
- 1999-11-09 CZ CZ20011631A patent/CZ20011631A3/cs unknown
-
2001
- 2001-05-07 NO NO20012245A patent/NO320647B1/no unknown
- 2001-05-25 HR HR20010402A patent/HRP20010402A2/hr not_active Application Discontinuation
- 2001-06-11 BG BG105588A patent/BG65371B1/bg unknown
-
2002
- 2002-05-14 HK HK02103628A patent/HK1041882A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3409668A (en) * | 1964-11-07 | 1968-11-05 | Palazzo Giuseppe | Substituted anthranilamides and process for the preparation thereof |
DE2652144A1 (de) * | 1976-11-16 | 1978-05-18 | Merck Patent Gmbh | Neue chinazolindione |
DE3406416A1 (de) * | 1983-02-28 | 1984-08-30 | American Cyanamid Co., Wayne, N.J. | N-((omega)-(1h-imidazol-l-yl)-alkyl)-arylamide |
EP0564356A1 (fr) * | 1992-04-01 | 1993-10-06 | Fournier Industrie Et Sante | Dérivés de 4-phénylaminométhylimidazole, procédé de préparation, antagonistes des récepteurs angiotensin II et leur application en thérapeutique |
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, vol. 85, no. 3, 19. Juli 1976 (1976-07-19) Columbus, Ohio, US; abstract no. 21433p, NODA, KANJI ET AL: "Quinazoline compounds" Seite 701; XP002135867 & JP 50 157383 A (HISAMITSU PHARMACEUTICAL CO., LTD., JAPAN) 19. Dezember 1975 (1975-12-19) * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US MONTGINOUL, C. ET AL: "Analgesic, anticonvulsant and anti-inflammatory activities of 1H,3H-quinazoline-2,4-diones" retrieved from STN Database accession no. 110:165551h XP002135868 & ANN. PHARM. FR. (1989), 46(4), 223-32, * |
HARDTMANN, GOETZ E. ET AL: "Chemistry of 2H-3,1-benzoxazine-2,4(1H)-dione (isatoic anhydrides). 1. Synthesis of N-substituted 2H-3,1-benzoxazine-2,4(1H)-diones" JOURNAL OF HETEROCYCLIC CHEMISTRY., Bd. 12, Nr. 3, 1975, Seiten 565-572, XP002135866 HETEROCORPORATION. PROVO., US ISSN: 0022-152X * |
PASTOR, G. ET AL: "Synthesis of new 1H,3H-quinazoline-2,4-diones" BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE., Bd. 5-6, Nr. 2, 1975, Seiten 1331-1338, XP002135865 SOCIETE FRANCAISE DE CHIMIE. PARIS., FR ISSN: 0037-8968 * |
Cited By (224)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129245B2 (en) * | 1998-12-23 | 2006-10-31 | Eli Lilly And Company | Aromatic amides |
WO2001085719A1 (de) * | 2000-05-09 | 2001-11-15 | Schering Aktiengesellschaft | Ortho substituierte anthranilsäureamide und deren verwendung als arzneimittel |
WO2001085671A2 (de) * | 2000-05-09 | 2001-11-15 | Schering Aktiengesellschaft | Anthranylamide und deren verwendung als arzneimittel |
US6818661B2 (en) * | 2000-05-09 | 2004-11-16 | Novartis Ag | Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors |
WO2001085671A3 (de) * | 2000-05-09 | 2002-04-11 | Schering Ag | Anthranylamide und deren verwendung als arzneimittel |
US7012081B2 (en) | 2000-05-09 | 2006-03-14 | Schering Ag | Anthranyl amides and their use as medicaments |
US7081468B2 (en) | 2000-05-09 | 2006-07-25 | Schering Ag | Ortho-substituted anthranilic acid amides and their use as medicaments |
US7479491B2 (en) * | 2000-05-09 | 2009-01-20 | Novartis Ag | Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors |
US6963000B2 (en) | 2000-06-21 | 2005-11-08 | Hoffman-La Roche Inc. | Benzothiazole derivatives with activity as adenosine receptor ligands |
US7317007B2 (en) | 2000-06-21 | 2008-01-08 | Hoffmann-La Roche Inc. | Benzothiazole derivatives with activity as adenosine receptor ligands |
WO2001097786A3 (en) * | 2000-06-21 | 2002-12-12 | Hoffmann La Roche | Benzothiazole derivatives |
US6835732B2 (en) | 2000-06-21 | 2004-12-28 | Hoffman-La Roche Inc. | Benzothiazole derivatives with activity as adenosine receptor ligands |
WO2001097786A2 (en) * | 2000-06-21 | 2001-12-27 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
US6521754B2 (en) | 2000-06-21 | 2003-02-18 | Hoffman-La Roche Inc. | Benzothiazole derivatives with activity as adenosine receptor ligands |
AU2001281817B2 (en) * | 2000-06-21 | 2005-11-24 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
WO2002046181A3 (en) * | 2000-12-07 | 2002-12-27 | Cv Therapeutics Inc | Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
AU2002225978B2 (en) * | 2000-12-07 | 2005-08-11 | Gilead Palo Alto, Inc. | ABCA-1 elevating compounds against coronary artery disease or atherosclerosis |
US6548548B2 (en) | 2000-12-07 | 2003-04-15 | Cv Therapeutics, Inc. | ABCA-1 elevating compounds |
WO2002046181A2 (en) * | 2000-12-07 | 2002-06-13 | Cv Therapeutics, Inc. | Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
WO2002066470A1 (en) * | 2001-01-12 | 2002-08-29 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
EP1798230A1 (en) * | 2001-01-12 | 2007-06-20 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7101868B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7514564B2 (en) | 2001-01-12 | 2009-04-07 | Amgen Inc. | Substituted amine derivatives and methods of use |
CN1313464C (zh) * | 2001-01-12 | 2007-05-02 | 安姆根有限公司 | 取代的烷基胺衍生物、其制备方法、含其的组合物及其用途 |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002068406A3 (en) * | 2001-01-12 | 2003-04-24 | Amgen Inc | Substituted amine derivatives and their use for the treatment of angiogenesis |
EP2311808A1 (en) | 2001-01-12 | 2011-04-20 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
CZ303356B6 (cs) * | 2001-01-12 | 2012-08-08 | Amgen Inc. | Substituovaný alkylaminový derivát a farmaceutická kompozice s jeho obsahem |
US8058445B2 (en) | 2001-01-12 | 2011-11-15 | Amgen Inc. | Substituted pyridinecarboxamides for the treatment of cancer |
US8642624B2 (en) | 2001-01-12 | 2014-02-04 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
EP2311829A1 (en) | 2001-01-12 | 2011-04-20 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002055501A3 (en) * | 2001-01-12 | 2002-12-19 | Amgen Inc. | N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
BG66160B1 (bg) * | 2001-01-12 | 2011-09-30 | Amgen Inc. | Заместени алкиламинови производни и използването им |
US7687643B2 (en) | 2001-01-12 | 2010-03-30 | Amgen Inc. | Process for preparing 3,3-dimethylindolines |
EP3345602A1 (en) | 2001-02-19 | 2018-07-11 | Novartis AG | Rapamycin derivative for treating advanced solid tumours |
EP2783686A1 (en) | 2001-02-19 | 2014-10-01 | Novartis AG | Combination of a rapamycin derivative and letrozole for treating breast cancer |
EP3406249A1 (en) | 2001-02-19 | 2018-11-28 | Novartis AG | Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor |
EP3351246A1 (en) | 2001-02-19 | 2018-07-25 | Novartis AG | Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis |
EP3342411A1 (en) | 2001-02-19 | 2018-07-04 | Novartis AG | Rapamycin derivative for treating pancreas cancer |
EP2762140A1 (en) | 2001-02-19 | 2014-08-06 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
EP2269603A1 (en) | 2001-02-19 | 2011-01-05 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
EP2269604A1 (en) | 2001-02-19 | 2011-01-05 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
EP2764865A2 (en) | 2001-02-19 | 2014-08-13 | Novartis AG | Cancer treatment |
US6864255B2 (en) | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
WO2003000678A1 (de) * | 2001-05-08 | 2003-01-03 | Schering Aktiengesellschaft | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
DE10123573A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel |
WO2002090352A2 (de) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
US7429592B2 (en) | 2001-05-08 | 2008-09-30 | Schering Aktienegesellschaft | Cyanoanthranilamide derivatives and the use thereof as medicaments |
DE10123587B4 (de) * | 2001-05-08 | 2005-04-07 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel |
JP2004528379A (ja) * | 2001-05-08 | 2004-09-16 | シエーリング アクチエンゲゼルシャフト | Vegfr−2およびvegfr−3インヒビターとしての選択的アントラニルアミドピリジンアミド |
WO2002090349A1 (de) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel |
DE10123587A1 (de) * | 2001-05-08 | 2002-11-21 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel |
DE10123573B4 (de) * | 2001-05-08 | 2005-06-02 | Schering Ag | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel |
WO2002090352A3 (de) * | 2001-05-08 | 2003-05-01 | Schering Ag | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
US7459470B2 (en) | 2001-05-08 | 2008-12-02 | Schering Ag | N-oxide anthranylamide derivatives and their use as medicaments |
EP2253319A1 (en) | 2001-05-16 | 2010-11-24 | Novartis AG | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. |
US7199147B2 (en) | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
WO2002100833A1 (fr) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
JPWO2002100833A1 (ja) * | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Rhoキナーゼ阻害剤 |
EP2210643A2 (en) | 2001-07-19 | 2010-07-28 | Novartis AG | Combinations comprising epothilones and pharmaceutical uses thereof |
US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
US7635774B2 (en) | 2001-10-09 | 2009-12-22 | Amgen Inc. | Benzimidazole derivatives |
CN1300113C (zh) * | 2001-11-08 | 2007-02-14 | 诺瓦提斯公司 | 邻氨基苯甲酰胺和其作为vegf受体酪氨酸激酶抑制剂的用途 |
EP2308855A1 (en) | 2002-03-15 | 2011-04-13 | Novartis AG | 2,4-Diaminopyrimidine derivatives |
EP1955696A2 (en) | 2002-05-16 | 2008-08-13 | Novartis AG | Use of EDG receptor binding agents in cancer |
EP1944026A2 (en) | 2002-05-16 | 2008-07-16 | Novartis AG | Use of EDG receptor binding agents in cancer |
AU2003256481B2 (en) * | 2002-07-09 | 2007-08-09 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
JP2006502112A (ja) * | 2002-07-09 | 2006-01-19 | アムジエン・インコーポレーテツド | 置換アントラニルアミド誘導体および使用方法 |
WO2004005279A2 (en) * | 2002-07-09 | 2004-01-15 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
WO2004005279A3 (en) * | 2002-07-09 | 2004-03-11 | Amgen Inc | Substituted anthranilic amide derivatives and methods of use |
WO2004007458A1 (en) | 2002-07-17 | 2004-01-22 | Amgen Inc. | Substituted 2-alkylamine nicotinic amide derivatives and use there of |
WO2004007481A2 (en) * | 2002-07-17 | 2004-01-22 | Amgen Inc. | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
WO2004007481A3 (en) * | 2002-07-17 | 2004-02-19 | Amgen Inc | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
US7094789B2 (en) | 2002-07-22 | 2006-08-22 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivatives |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
DE10235690A1 (de) * | 2002-07-31 | 2004-02-19 | Schering Ag | VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide |
EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
JP2005538123A (ja) * | 2002-08-07 | 2005-12-15 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アシルアミノ−置換複素芳香族化合物および医薬としてのそれらの使用 |
JP4778230B2 (ja) * | 2002-08-07 | 2011-09-21 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アシルアミノ−置換複素芳香族化合物および医薬としてのそれらの使用 |
WO2004014369A1 (en) * | 2002-08-07 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US7365070B2 (en) | 2002-12-04 | 2008-04-29 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
WO2004050610A2 (en) * | 2002-12-04 | 2004-06-17 | Gene Logic Inc. | Modulators of melanocortin receptor |
US7790719B2 (en) | 2002-12-04 | 2010-09-07 | Ore Pharmaceuticals, Inc. | Modulators of melanocortin receptor |
WO2004050610A3 (en) * | 2002-12-04 | 2004-08-26 | Millennium Pharm Inc | Modulators of melanocortin receptor |
US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
US6949563B2 (en) | 2003-01-06 | 2005-09-27 | Graham Michael Wynne | (2-carboxamido)(3-amino)thiophene compounds |
WO2004063330A2 (en) | 2003-01-06 | 2004-07-29 | Osi Pharmaceuticals, Inc. | (2-carboxamido) (3-amino) thiophene compounds |
US7087761B2 (en) | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
WO2004069792A3 (en) * | 2003-02-03 | 2005-01-20 | Janssen Pharmaceutica Nv | Quinoline-derived amide modulators of vanilloid vr1 receptor |
EP2308848A1 (en) * | 2003-02-03 | 2011-04-13 | Janssen Pharmaceutica NV | Quinoline-derived amide modulators of vanilloid VR1 receptor |
US8394828B2 (en) | 2003-02-03 | 2013-03-12 | Janssen Pharmaceutica, Nv | Quinoline-derived amide modulators of vanilloid VR1 receptor |
WO2004072069A1 (en) * | 2003-02-14 | 2004-08-26 | Glaxo Group Limited | Carboxamide derivatives |
US7531558B2 (en) | 2003-02-14 | 2009-05-12 | Glaxo Group Limited | Carboxamide derivatives |
WO2004078723A1 (ja) | 2003-03-07 | 2004-09-16 | Santen Pharmaceutical Co. Ltd. | 4-ピリジルアルキルチオ基を置換基として有する新規化合物 |
US8518973B2 (en) | 2003-03-07 | 2013-08-27 | Santen Pharmaceutical Co., Ltd. | Compounds having 4-pyridylalkylthio group as a substituent |
US8207194B2 (en) | 2003-03-07 | 2012-06-26 | Santen Pharmaceutical Co., Ltd. | Compounds having a 4-pyridylalkylthio group as a substituent |
EP2527326A1 (en) | 2003-03-07 | 2012-11-28 | Santen Pharmaceutical Co., Ltd | Novel compounds having 4-pyridylalkylthio group as substituent |
US7534802B2 (en) | 2003-03-07 | 2009-05-19 | Santen Pharmaceutical Co., Ltd. | Compounds having 4-pyridylalkylthio group as substituent |
WO2004103306A2 (en) | 2003-05-19 | 2004-12-02 | Irm Llc | Immunosuppressant compounds and compositions |
WO2005000833A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
EP3272736A1 (en) | 2003-05-19 | 2018-01-24 | Novartis Ag | Immunosuppressant compounds and compositions |
EP2644195A1 (en) | 2003-05-19 | 2013-10-02 | Irm Llc | Immunosuppressant Compounds and Compositions |
EP2514743A1 (en) | 2003-05-19 | 2012-10-24 | Irm Llc | Immunosuppressant Compounds and Compositions |
WO2004108133A2 (en) * | 2003-06-05 | 2004-12-16 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
WO2004108133A3 (en) * | 2003-06-05 | 2005-03-31 | Vertex Pharma | Modulators of vr1 receptor |
JP2006526660A (ja) * | 2003-06-05 | 2006-11-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vr1レセプターのモジュレーター |
WO2004111005A1 (de) * | 2003-06-13 | 2004-12-23 | Schering Aktiengesellschaft | Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyridone |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
US7989462B2 (en) | 2003-07-03 | 2011-08-02 | Myrexis, Inc. | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2005004864A1 (en) * | 2003-07-11 | 2005-01-20 | Merck Patent Gmbh | Benzimidazole derivatives as raf kinase inhibitors |
US7691886B2 (en) | 2003-07-11 | 2010-04-06 | Merck Patent Gmbh | Benzimidazole derivatives as raf kinase inhibitors |
WO2005047273A1 (en) * | 2003-11-14 | 2005-05-26 | Novartis Ag | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors |
WO2005054179A2 (en) | 2003-12-03 | 2005-06-16 | Leo Pharma A/S | Hydroxamic acid esters and pharmaceutical use thereof |
US7544703B2 (en) | 2004-02-17 | 2009-06-09 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein |
WO2005085202A1 (de) * | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Pyridinamid-derivate als kinase-inhibitoren |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
WO2005085188A3 (en) * | 2004-03-02 | 2006-06-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
US7368446B2 (en) | 2004-05-24 | 2008-05-06 | Hoffmann-La Roche Inc. | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
EP2409969A1 (en) | 2004-06-24 | 2012-01-25 | Novartis AG | Pyrimidine urea derivatives as kinase inhibitors |
EP2418205A1 (en) | 2004-06-24 | 2012-02-15 | Novartis AG | Pyrimidine urea derivatives as kinase inhibitors |
WO2006047574A1 (en) | 2004-10-26 | 2006-05-04 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-amino) thiophene compounds |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
JP2008518893A (ja) * | 2004-11-03 | 2008-06-05 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 血管内皮成長因子(vegf)受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア |
JP2008518894A (ja) * | 2004-11-03 | 2008-06-05 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Vegf受容体キナーゼインヒビターとしてのアントラニルアミドピリジンウレア |
US7572794B2 (en) | 2004-11-03 | 2009-08-11 | Bayer Schering Pharma Ag | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US7902229B2 (en) | 2004-11-03 | 2011-03-08 | Bayer Schering Pharma Ag | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US7459563B2 (en) | 2004-11-05 | 2008-12-02 | Hoffmann-La Roche Inc. | Process for the preparation of isonicotinic acid derivatives |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
US7897774B2 (en) | 2005-03-03 | 2011-03-01 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having quinolylalkylthio group |
US8063048B2 (en) | 2005-03-23 | 2011-11-22 | Hoffmann-La Roche Inc. | Acetylenyl-pyrazolo-pyrimidine derivatives |
US7718661B2 (en) | 2005-03-23 | 2010-05-18 | Hoffmann-La Roche Inc. | Acetylenyl-pyrazolo-pyrimidine derivatives |
US7238808B2 (en) | 2005-03-23 | 2007-07-03 | Hoffmann-La Roche Inc. | Acetylenyl-pyrazolo-pyrimidine derivatives |
US7446113B2 (en) | 2005-03-23 | 2008-11-04 | Hoffman-La Roche Inc. | Acetylenyl-pyrazolo-pyrimidine derivatives |
US7906511B2 (en) | 2005-03-31 | 2011-03-15 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having pyrimidinylalkylthio group |
US8507485B2 (en) | 2005-03-31 | 2013-08-13 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having pyrimidinylalkylthio group |
EP2292617A1 (en) | 2005-05-20 | 2011-03-09 | Novartis AG | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors |
EP2270008A1 (en) | 2005-05-20 | 2011-01-05 | Novartis AG | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors |
US8093263B2 (en) | 2005-09-27 | 2012-01-10 | Hoffmann-La Roche Inc. | Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists |
WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
US7504404B2 (en) | 2005-09-27 | 2009-03-17 | Hoffmann-La Roche Inc. | Compounds as metabotropic glutamate receptor antagonists |
US8349844B2 (en) | 2005-09-27 | 2013-01-08 | Hoffmann-La Roche Inc. | Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists |
EP2022498A2 (en) | 2005-11-21 | 2009-02-11 | Novartis AG | Neuroendocrine tumour treatment |
EP2275103A2 (en) | 2005-11-21 | 2011-01-19 | Novartis AG | mTOR inhibitors in the treatment of endocrine tumors |
US8106190B2 (en) * | 2005-11-30 | 2012-01-31 | Astellas Pharma Inc. | 2-aminobenzamide derivatives |
US8232298B2 (en) | 2006-03-22 | 2012-07-31 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between MDM2 and P53 |
WO2007107543A1 (en) | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
EP2272511A1 (en) | 2006-05-09 | 2011-01-12 | Novartis AG | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
EP3797765A1 (en) | 2006-06-27 | 2021-03-31 | Novartis AG | S1p receptor modulators for treating multiple sclerosis |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
US8063034B2 (en) | 2007-01-29 | 2011-11-22 | Santen Pharmaceutical Co., Ltd. | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity |
WO2008093677A1 (ja) | 2007-01-29 | 2008-08-07 | Santen Pharmaceutical Co., Ltd. | 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体 |
EP2359818A1 (en) | 2007-02-15 | 2011-08-24 | Novartis AG | Combination of LBH589 with HSP 90 inhibitors for treating cancer |
EP2491923A2 (en) | 2007-02-15 | 2012-08-29 | Novartis AG | Combinations of therapeutic agents for treating cancer |
EP1975166A1 (en) * | 2007-03-30 | 2008-10-01 | Bayer Schering Pharma AG | Synthesis of anthranilamides |
WO2008119569A1 (en) * | 2007-03-30 | 2008-10-09 | Bayer Schering Pharma Aktiengesellschaft | Synthesis of anthranilamides |
US8853406B2 (en) | 2007-08-06 | 2014-10-07 | Janssen Pharmaceutica Nv | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53 |
EP2628726A1 (en) | 2008-03-26 | 2013-08-21 | Novartis AG | Hydroxamate-based inhibitors of deacetylases b |
WO2010022725A1 (en) | 2008-08-27 | 2010-03-04 | Leo Pharma A/S | Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
WO2010043050A1 (en) | 2008-10-16 | 2010-04-22 | Celator Pharmaceuticals Corporation | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
WO2010080409A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid |
WO2010080455A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | New salts |
WO2010071794A1 (en) | 2008-12-18 | 2010-06-24 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
US8541442B2 (en) | 2009-02-04 | 2013-09-24 | Janssen Pharmaceutica N.V. | Indole derivatives as anticancer agents |
WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
WO2011015652A1 (en) | 2009-08-07 | 2011-02-10 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators |
WO2011018454A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
WO2011022439A1 (en) | 2009-08-17 | 2011-02-24 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
WO2011023677A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
WO2011029915A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
WO2011054828A1 (en) | 2009-11-04 | 2011-05-12 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
WO2011064211A1 (en) | 2009-11-25 | 2011-06-03 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
WO2011070030A1 (en) | 2009-12-08 | 2011-06-16 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2011076786A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
WO2011157793A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2011157787A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012066095A1 (en) | 2010-11-19 | 2012-05-24 | Novartis Ag | Crystalline form of an inhibitor of mdm2/4 and p53 interaction |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
WO2012120469A1 (en) | 2011-03-08 | 2012-09-13 | Novartis Ag | Fluorophenyl bicyclic heteroaryl compounds |
WO2012149413A1 (en) | 2011-04-28 | 2012-11-01 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012168884A1 (en) | 2011-06-09 | 2012-12-13 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
WO2013096059A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096049A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096055A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096051A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096060A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EP3064502A1 (en) | 2012-01-26 | 2016-09-07 | Novartis AG | Imidazopyrrolidinone compounds |
EP3272754A1 (en) | 2012-01-26 | 2018-01-24 | Novartis AG | Imidazopyrrolidinone compounds |
US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
US10844026B2 (en) | 2012-03-16 | 2020-11-24 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of riluzole and their method of use |
US11440893B2 (en) | 2012-03-16 | 2022-09-13 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of riluzole and their method of use |
US10562870B2 (en) | 2012-03-16 | 2020-02-18 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of riluzole and their method of use |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
EP3964513A1 (en) | 2012-04-03 | 2022-03-09 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022662A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2016016822A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
WO2019077037A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY |
WO2019119486A1 (zh) | 2017-12-21 | 2019-06-27 | 中国科学院合肥物质科学研究院 | 一类嘧啶类衍生物激酶抑制剂 |
US11602534B2 (en) | 2017-12-21 | 2023-03-14 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Pyrimidine derivative kinase inhibitors |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
Also Published As
Publication number | Publication date |
---|---|
NO20012245L (no) | 2001-07-10 |
BG65371B1 (bg) | 2008-04-30 |
PL348349A1 (en) | 2002-05-20 |
YU31801A (sh) | 2003-12-31 |
HUP0104425A2 (hu) | 2002-03-28 |
KR100777476B1 (ko) | 2007-11-16 |
EA200100524A1 (ru) | 2002-02-28 |
US7122547B1 (en) | 2006-10-17 |
KR100855396B1 (ko) | 2008-08-29 |
TR200101307T2 (tr) | 2002-05-21 |
EE200100258A (et) | 2002-12-16 |
NZ511413A (en) | 2004-01-30 |
CA2350208A1 (en) | 2000-05-18 |
CN1325384A (zh) | 2001-12-05 |
CN1151133C (zh) | 2004-05-26 |
UA71587C2 (uk) | 2004-12-15 |
AU1045400A (en) | 2000-05-29 |
HRP20010402A2 (en) | 2003-10-31 |
NO320647B1 (no) | 2006-01-09 |
BR9915553A (pt) | 2001-08-14 |
KR20070087027A (ko) | 2007-08-27 |
EP1129074A2 (de) | 2001-09-05 |
AU771180B2 (en) | 2004-03-18 |
EA004701B1 (ru) | 2004-06-24 |
BG105588A (en) | 2002-04-30 |
HUP0104425A3 (en) | 2003-05-28 |
KR20010075689A (ko) | 2001-08-09 |
WO2000027819A3 (de) | 2000-08-17 |
HK1041882A1 (en) | 2002-07-26 |
CZ20011631A3 (cs) | 2001-10-17 |
NO20012245D0 (no) | 2001-05-07 |
SK6072001A3 (en) | 2002-01-07 |
JP2002529452A (ja) | 2002-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000027819A2 (de) | Anthranilsäureamide und deren verwendung als arzneimittel | |
EP1280776B1 (de) | Substituierte benzoesäureamide und deren verwendung zur hemmung von angiogenese | |
DE10023486C1 (de) | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel | |
WO2001085715A2 (de) | Aza- und polyazanthranylamide und deren verwendung als arzneimittel | |
WO2001085671A2 (de) | Anthranylamide und deren verwendung als arzneimittel | |
WO2001085691A1 (de) | Anthranylalkyl- und -cycloalkylamide und deren verwendung als vegf-rezeptorenhemmer | |
JP2002529452A5 (US07122547-20061017-C00064.png) | ||
EP1387838B1 (de) | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel | |
WO2002090349A1 (de) | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel | |
DE19910396C2 (de) | Anthranilsäureamide und deren Verwendung als Arzneimittel | |
EP0068240B1 (de) | 2-Acylaminomethyl-1,4-benzodiazepin-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE10123573B4 (de) | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel | |
DE10123587B4 (de) | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel | |
DE10125295A1 (de) | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) | |
DE10125293A1 (de) | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) | |
MXPA01004692A (en) | Antrhranilic acid amides and the use thereof as medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-318/01 Country of ref document: YU Ref document number: 99813078.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2000 10454 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999953967 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 142618 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/00422/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 511413 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: A 2001 00481 Country of ref document: RO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6072001 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2350208 Country of ref document: CA Ref document number: 2350208 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017005800 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 580999 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-1631 Country of ref document: CZ Ref document number: 10454/00 Country of ref document: AU Ref document number: 2001/01307 Country of ref document: TR Ref document number: PA/a/2001/004692 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20010402A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/04673 Country of ref document: ZA Ref document number: 200104673 Country of ref document: ZA Ref document number: 200100524 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 1999 105588 Country of ref document: BG Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017005800 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999953967 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09831506 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-1631 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 10454/00 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017005800 Country of ref document: KR |